Corcept Therapeutics CORT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's total liabilities?
- Corcept Therapeutics (CORT) reported total liabilities of $176.89M in Q1 2026.
- How has Corcept Therapeutics's total liabilities changed year-over-year?
- Corcept Therapeutics's total liabilities increased by 8.4% year-over-year, from $163.17M to $176.89M.
- What is the long-term trend for Corcept Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total liabilities has grown at a 31.3% compound annual growth rate (CAGR), from $48.39M to $188.85M.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors.
- How do you interpret total liabilities?
- A rising trend may indicate aggressive financing or expansion, while a decreasing trend suggests deleveraging and improved financial stability.
- How does total liabilities compare across companies?
- Standard financial metric; peers are assessed based on their debt-to-equity and total liability-to-asset ratios.